Oncology Drugs revenue Poland 2017-2029

The revenue in the 'Oncology Drugs' segment of the pharmaceuticals market in Poland was forecast to continuously increase between 2024 and 2029 by in total 226.2 million U.S. dollars (+37.48 percent). After the seventh consecutive increasing year, the indicator is estimated to reach 829.65 million U.S. dollars and therefore a new peak in 2029.

Find further information concerning the revenue in the pharmaceuticals market in Argentina and the revenue in the pharmaceuticals market in China.

The Statista Market Insights cover a broad range of additional markets.

Revenue in the Oncology Drugs segment in Poland from 2017 to 2029 (in million U.S. dollars)

Characteristic	In million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

Definition:
The Oncology Drugs market covers drugs to treat cancer, including chemotherapy and immunotherapy. These therapies are used for solid tumors and hematologic cancer. The medications in this market are mainly physician-administered drugs.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Johnson & Johnson

Citation formats